http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Foundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration with Merck
-
Foundation Medicine Receives New ADLT Status for FoundationOne CDx™ from the Centers for Medicare and Medicaid Services (CMS)
-
Genentech to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in People With Hemophilia A at the World Federation of Hemophilia 2018 World Congress
-
Foundation Medicine Announces 2018 First Quarter Results and Recent Highlights
-
Foundation Medicine Launches Gene Expression Profiling Program to Identify Known and Novel Biomarkers in Advanced Cancer
-
Foundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance Personalized Cancer Care in China
-
Foundation Medicine (FMI) Says New Liquid Biopsy Assay Granted Breakthrough Device Designation
-
Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration
-
Foundation Medicine Announces Timing for First Quarter 2018 Financial Results and Conference Call
-
Foundation Medicine (FMI), Collaborators Present New Findings Supporting Tissue- and Blood-based Comprehensive Genomic Profiling
-
Foundation Medicine and its Collaborators Present New Findings Supporting Tissue- and Blood-based Comprehensive Genomic Profiling (CGP) to Inform Targeted and Cancer Immunotherapy Treatment Strategies
-
Cancer Treatment Centers of America and Foundation Medicine Launch Joint Educational Campaign to Raise Consumer Awareness of Precision Medicine Approaches in Cancer Care
-
Foundation Medicine Announces Commercial Availability of FoundationOne CDx™, the First FDA-Approved Comprehensive Genomic Profiling Assay for All Solid Tumors Incorporating Multiple Companion Diagno
-
Foundation Medicine Announces Final National Coverage Determination (NCD) from the Centers for Medicare & Medicaid Services (CMS), Including Coverage for FoundationOne CDx™ Across All Solid Tumo
-
Foundation Medicine Advances Patient Access to Precision Medicine; Pursues Regulatory Approval for FoundationOne CDx™ in Japan
-
Foundation Medicine and Guardant Health Agree to Resolve False Advertising Lawsuit
-
Foundation Medicine to Present at Cowen and Company’s 38th Annual Healthcare Conference
-
Foundation Medicine Announces 2017 Fourth Quarter and Year-End Results, Recent Highlights and 2018 Outlook
-
Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2017 Financial Results and Conference Call
-
Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC)
-
Foundation Medicine and European Organisation for Research and Treatment of Cancer (EORTC) Announce Collaboration to Advance Precision Medicine Using Comprehensive Genomic Profiling to Facilitate Clin
-
Foundation Medicine (FMI), Pfizer (PFE) Announce Pact to Develop Companion Diagnostics for Pfizer's Oncology Portfolio
-
Foundation Medicine and Pfizer Announce Broad Partnership to Develop Companion Diagnostics for Pfizer’s Oncology Portfolio
-
Foundation Medicine (FMI) Prelim. Q4 Revenue Tops Views
-
Foundation Medicine Reports Preliminary 2017 Results
-
GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment
-
Foundation Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
